2018 Report: Real World Evidence Has Demonstrated the Potential to Validate the Therapeutic Value of Pharmaceutical Products and Help Customize Product Development in a More Patient Centric Manner

News provided by

Nov 20, 2018, 17:30 ET

DUBLIN, Nov. 20, 2018 /PRNewswire/ --

The "Real World Evidence: Market Landscape and Competitive Insights, 2018-2030" report has been added to ResearchAndMarkets.com's offering.

The Real World Evidence: Market Landscape and Competitive Insights, 2018-2030' report features an extensive study on the industry players that are offering real-world data/analytics/services to the pharmaceutical and life sciences industries.

Example Highlights

Close to 200 players are actively involved in providing real-world evidence-based insights into the pharmaceutical industry. Of these, around 45% offer a range of services for real-world evidence generation. Examples of such players include (in alphabetical order, no specific selection criteria) Clinigen Group, HealthCore, ICON, Ingress Health, IQVIA, PAREXEL, pH Associates, Quantzig, and Syneos Health. These are followed by companies that offer analytical platforms (39%) and real-world datasets (16%). Examples of such players include (in alphabetical order, no specific selection criteria) Aetion, Flatiron Health, IBM Watson Health, Linguamatics, PatientsLikeMe, RealHealthData, Saama Technologies, SHYFT Analytics, Tempus, TriNetX, and uMotif.
More than 120 real-world data/analytics/service providers utilize clinical data derived from medical and patient care records, such as electronic health records, clinical registries, genomic data repositories, lab tests results, and pathology data. These are followed by companies (over 100) that claim to use patient experience data for generating actionable insights. Other datasets that are commonly used by stakeholders in this industry include (but not limited to) medical claims data, clinical trials data and pharmacy data.
Leveraging the aforementioned data, close to 145 companies are engaged in providing actionable, evidence-based insights for post-approval research. Other key application areas of real-world evidence include (in decreasing order of the number of companies) clinical development (~65%), regulatory approval/reimbursement/market access (~56%), and early-stage research (~54%).
The current market landscape is characterized by the presence large companies (more than 500 employees,27%), mid-sized companies (50-500 employees, 30%), and small-sized companies (less than 50 employees, 43%). The majority of these companies (~60%) are located in North America; examples of players based in this region include (in alphabetical order, no specific selection criteria) Allscripts, Cota Healthcare, Decision Resources Group, Ephicacy, Indegene, Knowledgent, MarkLogic, PerkinElmer, Pharmerit, SAS Institute, and Vector Oncology.
Extensive research efforts in this domain are reflected in the fact that over 500 scientific articles have been published since 2016. It is worth noting that, in 2018 (till June) alone, close to 180 articles were published related to the ongoing real-world data-based research. Industry stakeholders that have made significant contributions to the intellectual capital in this domain include (in decreasing order of the number of publications) Merck, IQVIA, GlaxoSmithKline, Eli Lilly, Novartis, PPD (Evidera), Janssen Pharmaceutica, AstraZeneca, Amgen, and Pfizer.
More than 1,000 clinical studies, conducted in a real-world setting, have been registered (completed/ongoing/planned) across different geographies. Based on the number of trials, North America (~460 trials) has emerged as a major research/innovation hub in this domain. It is also worth highlighting that a relatively larger proportion of the trials evaluated patients suffering from oncological disorders, cardiovascular disorders, neurological and psychiatric disorders.
The real world evidence solutions market is expected to grow at an annualized rate of 14.1% between 2018 and 2030. While the current opportunity of real-world evidence is maximum in post-approval studies, its scope in early-stage research and clinical development is anticipated to grow at a relatively faster rate in the forecast period. Further, North America and Europe presently dominate the market and are expected to retain the leading position over the next decade. This is followed by Asia-Pacific and the rest of the world, which currently captures around 10% of the overall market share. We are led to believe that this trend is not likely to change significantly in the foreseen future.

Key Topics Covered:

1. Preface
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. Executive Summary

3. Introduction
3.1. Need for Real World Evidence
3.1.1. Growing Crisis of Chronic Disorders
3.1.2. High Investment Involved in Drug Development
3.1.2.1. Role of Randomized Clinical Trials
3.1.2.2. Limitations of Randomized Clinical Trials
3.1.3. Increasing Shift from Volume- to Value-based Care
3.2. An Overview of Real World Evidence
3.2.1. Sources of Real World Data
3.2.1.1. Medical Claims Data
3.2.1.2. Clinical Trial Data
3.2.1.3. Clinical Settings Data
3.2.1.4. Patient-Powered Data
3.2.1.5. Pharmacy Data
3.2.1.6. Other Real World Data Sources
3.2.2. Comparison of Randomized Clinical Trials and Real World Evidence
3.2.3. Advantages and Limitations of Real World Evidence
3.2.4. Potential Applications of Real World Evidence
3.2.5. Growth Drivers and Challenges
3.3. Role of Advanced Techniques in Real World Data Management

4. Data Governance And Regulatory Framework For Real World Evidence
4.1. Chapter Overview
4.2. Primary Elements of Data Governance for Real World Evidence
4.3. Importance of Regulatory Framework for Real World Evidence
4.4. Data Governance and Regulatory Framework in North America
4.4.1. The US Scenario
4.4.1.1. Data Governance
4.4.1.2. Regulatory Framework
4.4.1.3. Future Recommendations
4.4.2. The Canadian Scenario
4.4.2.1. Data Governance
4.4.2.2. Regulatory Framework
4.4.2.3. Future Recommendations
4.5. Data Governance and Regulatory Framework in Europe
4.6. Data Governance and Regulatory Framework in Asia-Pacific

5. Current Market Landscape
5.1. Chapter Overview
5.2. List of Real World Evidence Solution Providers
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Geographical Location
5.2.3. Analysis by Company Size
5.2.4. Analysis by Type of Offering
5.2.5. Analysis by Real World Data Sources
5.2.6. Analysis by Applications of Real World Evidence

6. Publication Analysis
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. Real World Evidence: Publication Analysis
6.3.1. Analysis by Publication Year
6.3.2. Analysis by Key Focus Areas
6.3.3. Analysis by Real World Data Sources
6.3.4. Analysis by Key Indications Examined
6.3.5. Leading Players in Terms of Number of Published Studies
6.3.6. Analysis by Geographical Location of Leading Players
6.3.7. Key Journals

7. Clinical Trial Analysis
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Real World Evidence: Clinical Trial Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Geography and Number of Clinical Trials
7.3.3. Analysis by Geography and Enrolled Patient Population
7.3.4. Analysis by Trial Recruitment Status
7.3.5. Analysis by Type of Study
7.3.6. Analysis by Type of Sponsors / Collaborators
7.3.7. Most Active Players in Terms of Number of Trials
7.3.8. Analysis by Focus Areas
7.3.9. Analysis by Target Therapeutic Areas
7.3.10. Grid Analysis of Key Therapeutic Areas, 2013-2018
7.3.11. Benchmark Analysis of Key Industry Players

8. Emerging Trends On Social Media
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Real World Evidence: Trends on Twitter
8.3.1. Historical Trends in Volume of Tweets
8.3.2. Popular Keywords
8.3.3. Popular Sources of Real World Data
8.3.4. Popular Applications of Real World Evidence
8.3.5. Popular Therapeutic Areas
8.3.6. Popular Stakeholders
8.3.7. Most Prolific Contributors
8.3.8. Most Influential Contributors

9. Global Events Analysis
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Real World Evidence: Global Events Analysis
9.3.1. Analysis by Year of Occurrence
9.3.2. Analysis by Geography
9.3.3. Analysis by Type of Event
9.3.4. Analysis by Key Focus Area / Event Agenda
9.3.5. Most Active Event Organizers
9.3.6. Most Active Players in Terms of Event Participation
9.3.7. Analysis by Seniority Level of Participants
9.3.8. Geographical Mapping of Upcoming Events

10. SWOT Analysis
10.1. Chapter Overview
10.2. Comparison of SWOT Factors

11. Stakeholder Needs Analysis
11.1. Chapter Overview
11.2. Real World Evidence: Needs of Stakeholders
11.2.1. Comparison of Needs of Stakeholders

12. Real World Evidence Use Cases And Opportunity Assessment
12.1. Chapter Overview
12.2. Real World Evidence Use Cases
12.3. Real World Evidence Market Opportunity Assessment
12.3.1 Methodology and Key Assumptions
12.3.2. Global Real World Evidence Market Opportunity, 2018-2030
12.3.3. Global Real World Evidence Market Opportunity by Type of Datasets
12.3.3.1.Real World Evidence Market Opportunity from Medical Claims Data, 2018-2030
12.3.3.2. Real World Evidence Market Opportunity from Clinical Trials Data, 2018-2030
12.3.3.3. Real World Evidence Market Opportunity from Clinical Settings Data, 2018-2030
12.3.3.4. Real World Evidence Market Opportunity from Patient-Powered Data, 2018-2030
12.3.3.5. Real World Evidence Market Opportunity from Pharmacy Data, 2018-2030
12.3.3.6. Real World Evidence Market Opportunity from Other Types of Data, 2018-2030
12.3.4. Global Real World Evidence Market Opportunity by Therapeutic Areas
12.3.4.1.Real World Evidence Market Opportunity in Cardiovascular Disorders, 2018-2030
12.3.4.2.Real World Evidence Market Opportunity in Infectious Diseases, 2018-2030
12.3.4.3.Real World Evidence Market Opportunity in Metabolic Disorders, 2018-2030
12.3.4.4.Real World Evidence Market Opportunity in Neurological / Psychiatric Disorders, 2018-2030
12.3.4.5.Real World Evidence Market Opportunity in Oncological Disorders, 2018-2030
12.3.4.6.Real World Evidence Market Opportunity in Other Types of Disorders, 2018-2030
12.3.5. Global Real World Evidence Market Opportunity by Applications
12.3.5.1.Real World Evidence Market Opportunity in Early Stage Research, 2018-2030
12.3.5.2.Real World Evidence Market Opportunity in Clinical Development, 2018-2030
12.3.5.3.Real World Evidence Market Opportunity in Regulatory Approval, 2018-2030
12.3.5.4.Real World Evidence Market Opportunity in Pricing / Reimbursement, 2018-2030
12.3.5.5.Real World Evidence Market Opportunity in Post-Approval Studies, 2018-2030
12.3.6. Regional Market Opportunities for Real World Evidence
12.3.6.1.Real World Evidence Market Opportunity in North America, 2018-2030
12.3.6.2.Real World Evidence Market Opportunity in Europe, 2018-2030
12.3.6.3.Real World Evidence Market Opportunity in Asia-Pacific, 2018-2030
12.3.6.4.Real World Evidence Market Opportunity in Rest of the World, 2018-2030

13. Survey Insights
13.1. Chapter Overview
13.2. Seniority Level of Respondents
13.3. Type of Offering
13.4. Real World Data Sources
13.5. Applications of Real World Evidence
13.6. Key Challenges in Generating Real World Evidence
13.7. Extent of Outsourcing
13.8. Current Market Opportunity

14. Interview Transcripts
14.1. Chapter Overview
14.2. Jane Reed, Head of Life Science Strategy, Linguamatics
14.3. Jonathan Moshinsky, Head of Market Strategy, uMotif
14.4. Mark Cziraky, Vice President of Research, HealthCore
14.5. Anonymous, Vice President, Big Pharmaceutical Company

15. Appendix 1: Tabulated Data

16. Appendix 2: List Of Companies And Organizations

23andMe
8KMiles
Abbott
AbbVie
Acceliant
Accenture
Accsight
Adarna Health Data
Adelphi Real World
Advera Health Analytics
Aetion
Allscripts
Amazon Web Services
American College of Cardiology
American Diabetes Association
Amgen
Ana Health
Analytica Laser
Anthem
Apple
Arcana Institute
Astellas Pharma
AstraZeneca
Axonal-Biostatem
Axtria
Bayer
BC Platforms
Biogen
Boehringer Ingelheim
Boston Health Economics
Boston Scientific
Bristol-Myers Squibb
Cambridge Healthtech Institute
CardioVascular Research Foundation
CareFacets
Caros Connect
CBI
Cegedim Strategic Data
Centers for Disease Control and Prevention
Chinese Academy of Medical Sciences
CitiusTech
CK Aspire
Clarivate Analytics
Clinakos
ClinaMetrics
Clinerion
Clinical Trial EndPoint
Clinigen Group
Cloudera
CloudMoyo
Cogentia Healthcare Consulting
Cognizant
Conference Series
ConvergeHEALTH
Cota Healthcare
Crossix Solutions
Custodix
D Cube Analytics
Daichii Sankyo
Data2Life
Databricks
Decision Driver Analytics
Decision Resources
Defense Intelligence Agency
DIGIPHARM
Digital Health Labs
Drug Intelligence
Duke University
Dycros
Edwards Lifesciences
Eli Lilly
Elligo Health Research
Ephicacy
EPID Research
Ernst & Young
ESiOR
European Medicines Agency
Eurotrials
Evidence Based Solutions
Evidera
evoMetrics
eyeforpharma
Flatiron Health
Flex
Fuzzy Logix
Genentech
Genospace
GlaxoSmithKline
GNS Healthcare
Google
Harvard Medical School
Healint
Health IQ
Health Solutions
Healthagen
HealthCore
Healthing Research
HealThink
HealthVerity
Humana
Huron Consulting
IBM Watson Health
ICON
Ignite Data
Indegene
Infosys
Ingress Health
InnoWin
Inovalon
Insight Pharmaceuticals
Institute for Quality and Efficiency in Health Care
Insys Group
Intel
International Society for Pharmacoeconomics and Outcomes Research
IntrinsiQ Specialty Solutions
IQVIA
iwantGreatCare
Janssen Pharmaceutica
Johaus Global
Johnson & Johnson
Kaiku Health
Kantar Health
Karolinska Institutet
Keedio
Keyrus Biopharma
Knowledgent
Koneksa Health
Kx Systems
Lifecode Solutions
Linguamatics
LINK Medical Research
Lundbeck
LynxCare
M2Gen
M2S
MA Provider
MakroCare
Mapi Group
MarkLogic
MarksMan Healthcare Communications
Massachusetts General Hospital
MaxisIT
Mayo Clinic
McKesson
MDC Partners
MeaningCloud
Med-eShare
Medaffcon
MedEngine
Medical Wisdom Consulting Group
Medidata Solutions
Medlior Health Outcomes Research
Medpace
MedStreaming
Medtronic
Merck
Mercy
MyOwnMed
mySugr
National Academies of Sciences, Engineering and Medicine
National Cancer Institute
National Institute of Mental Health
National Institute on Drug Abuse
National Institutes of Health
National Investigation Agency
New England Research Institute
New York Heart Association
NJ YZ Clinical Trials and Consulting
Northern Alberta Clinical Trials and Research Centre
Novartis
Novo Nordisk
Numerus
Observational and Pragmatic Research Institute
Odysseus Data Services
OKRA Technologies
OM1
Omega CRO
Oncocare Health
OncoStats
Optra Systems
Optum
OptumInsight
Oracle
ORPHA Strategy Consulting
OXON Epidemiology
Palantir
PAREXEL
Patient-Centered Outcomes Research Institute
PatientsLikeMe
PatientSource
Peking University
Peripharm
PerkinElmer
Pfizer
pH Associates
Pharma Intelligence
Pharmaceuticals and Medical Devices Agency
Pharmerit International
PHARMO Institute
Pinscriptive
Point-of-Care Partners
PotentiaMED
PRA Health Sciences
Precision Digital Health
Precision Health AI
Premier
Qlik
Quantify Research
Quantzig
Raven Biosciences
Real Consulting Data
Real Life Sciences
RealHealthData
Revon Systems
Roam
Roche
RxAnte
S3 Connected Health
Saama Technologies
Sanofi
SAS Institute
Savana
Sciensus
Sciformix
Self Care Catalysts
Sentry Data Systems
SHYFT Analytics
Society of Thoracic Surgeons
Sprim Advanced Life Sciences
SQN Clinical
St. Jude Medical
Stanford University
StatFinn
Sutter Health
SVMPharma
Symphony Health Solutions
Syneos Health
Synergus
Syntel
T-Systems
Takeda Pharmaceutical
Talking Medicines
TCD Outcomes Research
Techtrials International
Tempus
Terrapinn Holdings
TFS
TransMed Systems
TriAxia Health
TriNetX
Truven Health Analytics
Turacoz Healthcare Solutions
uMotif
United BioSource
University of Alabama
University of California
University of Louisville
University of North Carolina
University of Pennsylvania
University of Pittsburgh
University of Texas
US Department of Defense
VA Office of Research and Development
Validic
Vector Oncology
Verana Health
Vestrum Health
Vitaccess
Vital Statistics Consulting
Washington University School of Medicine
Wellframe
West Monroe Partners
Wipro
World Congress
Worldwide Clinical Trials
Xcenda
Yale University
Zeblok
ZEINCRO
Zephyr Health
ZS Associates

For more information about this report visit https://www.researchandmarkets.com/research/7tkk8h/2018_report_real?w=5

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets